Bifogade filer
Kurs
-3,62%
Prenumeration
Kalender
Est. tid* | ||
2025-11-20 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-28 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-30 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2025-05-28 | - | Årsstämma |
2025-05-28 | - | Kvartalsrapport 2025-Q1 |
2025-02-20 | - | Bokslutskommuniké 2024 |
2024-11-21 | - | Kvartalsrapport 2024-Q3 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | Kvartalsrapport 2024-Q1 |
2024-05-16 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2024-05-15 | - | Årsstämma |
2024-02-27 | - | Extra Bolagsstämma 2024 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-11-28 | - | Kvartalsrapport 2023-Q3 |
2023-08-30 | - | Kvartalsrapport 2023-Q2 |
2023-05-30 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2023-05-29 | - | Årsstämma |
2023-05-29 | - | Kvartalsrapport 2023-Q1 |
2023-03-13 | - | Bokslutskommuniké 2022 |
2023-01-09 | - | Extra Bolagsstämma 2022 |
2022-11-28 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-06-02 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2022-06-01 | - | Årsstämma |
2022-05-24 | - | Kvartalsrapport 2022-Q1 |
2022-02-23 | - | Bokslutskommuniké 2021 |
2021-11-22 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-18 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2021-05-18 | - | Kvartalsrapport 2021-Q1 |
2021-05-17 | - | Årsstämma |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2020-05-14 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-28 | - | Kvartalsrapport 2019-Q3 |
2019-08-29 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2019-05-16 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-29 | - | Kvartalsrapport 2018-Q3 |
2018-08-30 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-09 | - | Kvartalsrapport 2017-Q3 |
2017-10-06 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-12 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2017-05-11 | - | Årsstämma |
2017-05-11 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-06-09 | - | Extra Bolagsstämma 2016 |
2016-04-22 | - | Årsstämma |
2016-04-22 | - | Kvartalsrapport 2016-Q1 |
2016-04-21 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2016-02-10 | - | Bokslutskommuniké 2015 |
2015-10-29 | - | Kvartalsrapport 2015-Q3 |
2015-08-13 | - | Kvartalsrapport 2015-Q2 |
2015-04-22 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
2015-04-21 | - | Årsstämma |
2015-04-21 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-11-11 | - | Kvartalsrapport 2014-Q3 |
2014-08-21 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Uppsala 15 March 2022 - LIDDS announced today that the company's new website, with updated content and design and improved functions, has been launched.
As part of ensuring good functionality and visualizing that LIDDS takes further steps in its development, the company has developed a new website. The website has updated content and a new graphic profile, which was also shown in the company's Year-end report and at the Capital Markets Day, which was held on 9 March. A link to the Capital Markets Day presentations and Q&A session can be found on the website, www.liddspharma.com.
For additional information, please contact
Nina Herne, CEO
Phone: +46 (0)70 714 74 57
E-mail: nina.herne@liddspharma.com
Jenni Björnulfson, CFO
Phone: +46 (0)708 55 38 05
E-mail: jenni.bjornulfson@liddspharma.com
LIDDS in brief:
LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.